|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Erbitux
|
|
gptkbp:advocates_for
|
obtained from participants
|
|
gptkbp:analysis
|
conducted
statistical analysis
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
|
|
gptkbp:business_model
|
received
|
|
gptkbp:clinical_trial
|
published in peer-reviewed journals
NC T01234567
|
|
gptkbp:collaborations
|
various universities
|
|
gptkbp:collection
|
surveys
|
|
gptkbp:committee
|
established
|
|
gptkbp:criteria
|
other malignancies
no prior chemotherapy
|
|
gptkbp:end_date
|
2015-12-31
|
|
gptkbp:events
|
2 years
|
|
gptkbp:focuses_on
|
gptkb:healthcare_organization
|
|
gptkbp:future_plans
|
recommended based on findings
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CRYSTAL trial
|
|
gptkbp:impact
|
guidelines for treatment
|
|
gptkbp:is_compared_to
|
standard treatment
|
|
gptkbp:is_protected_by
|
targeted therapy
|
|
gptkbp:is_studied_in
|
multi-center study
|
|
gptkbp:is_tested_for
|
Phase III
|
|
gptkbp:launch_date
|
2010-01-01
|
|
gptkbp:location
|
multiple sites
|
|
gptkbp:notable_work
|
significant efficacy
|
|
gptkbp:participants
|
over 1000
quality of life
overall survival
progression-free survival
|
|
gptkbp:population
|
diverse demographics
|
|
gptkbp:products
|
Drug A
Drug B
|
|
gptkbp:provides_information_on
|
available upon request
|
|
gptkbp:publishes
|
gptkb:Journal_of_Clinical_Oncology
|
|
gptkbp:receives_funding_from
|
government grants
|
|
gptkbp:recorded_by
|
randomized controlled trial
|
|
gptkbp:recruitment
|
ongoing during study period
|
|
gptkbp:research
|
interventional study
|
|
gptkbp:result
|
improved survival rates
submitted to regulatory bodies
|
|
gptkbp:side_effect
|
monitored
|
|
gptkbp:sponsor
|
gptkb:healthcare_organization
|
|
gptkbp:status
|
completed
|
|
gptkbp:student_enrollment
|
adults with metastatic colorectal cancer
|
|
gptkbp:treatment
|
control group
chemotherapy
experimental group
|
|
gptkbp:vision
|
open-label
|
|
gptkbp:year
|
2014-06-30
|